NCT07140237 The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
| NCT ID | NCT07140237 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Electronic Science and Technology of China |
| Condition | Healthy Adult Male |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-09 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 250 participants in total. It began in 2025-09 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of the present study is to investigate whether orally (lingual spray) administered oxytocin influences human top-down attention via oxytocin receptors and whether its effects are dose- and task-dependent.
Eligibility Criteria
Inclusion Criteria: * Healthy male subjects without past or current psychiatric or neurological disorders Exclusion Criteria: * History of or current neurological/psychiatric disorders; * Use of psychotropic medications (including nicotine) * Visual impairments
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07140237 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 35 Years, studying Healthy Adult Male. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07140237 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07140237 currently recruiting?
Yes, NCT07140237 is actively recruiting participants. Contact the research team at k.kendrick.uestc@gmail.com for enrollment information.
Where is the NCT07140237 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT07140237 clinical trial?
NCT07140237 is sponsored by University of Electronic Science and Technology of China. The trial plans to enroll 250 participants.